CoChat

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

Open access
Sperling, Adam S., Burgess, Michael, Keshishian, Hasmik, Gasser, Jessica A., Bhatt, Shruti, Jan, Max, Słabicki, Mikołaj, Sellar, Rob S., Fink, Emma C., Miller, Peter G., Liddicoat, Brian J., Sievers, Quinlan L., Sharma, Rohan, Adams, Dylan N., Olesinski, Elyse A., Fulciniti, Mariateresa, Udeshi, Namrata D., Kuhn, Eric, Letai, Anthony, Munshi, Nikhil C., Carr, Steven A., Ebert, Benjamin L. · 2019 · Blood
Cited by 64

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Pharmacologic agents that modulate ubiquitin ligase activity to induce protein degradation are a major new class of therapeutic agents, active in a number of hematologic malignancies. However, we currently have a limited understanding of the determinants of activity of these agents and how resistance develops. We developed and used a novel quantitative, targeted mass spectrometry (MS) assay to determine the relative activities, kinetics, and cell-type specificity of thalidomide and 4 analogs, all but 1 of which are in clinical use or clinical trials for hematologic malignancies. Thalidomide analogs bind the CRL4CRBN ubiquitin ligase and induce degradation of particular proteins, but each of the molecules studied has distinct patterns of substrate specificity that likely underlie the clinical activity and toxicities of each drug. Our results demonstrate that the activity of molecules that induce protein degradation depends on the strength of ligase-substrate interaction in the presence of drug, the levels of the ubiquitin ligase, and the expression level of competing substrates. These findings highlight a novel mechanism of resistance to this class of drugs mediated by competition between substrates for access to a limiting pool of the ubiquitin ligase. We demonstrate that increased expression of a nonessential substrate can lead to decreased degradation of other substrates that are critical for antineoplastic activity of the drug, resulting in drug resistance. These studies provide general rules that govern drug-dependent substrate degradation and key differences between thalidomide analog activity in vitro and in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019000789

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 15

  1. Fink, 2015, The novel mechanism of lenalidomide activity, Blood, 126, 2366, 10.1182/blood-2015-07-567958 · DOI · Paper page
  2. Heintel, 2013, High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone, Br J Haematol, 161, 695, 10.1111/bjh.12338 · DOI · Paper page
  3. Gillette, 2013, Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry, Nat Methods, 10, 28, 10.1038/nmeth.2309 · DOI · Paper page
  4. Ippoliti, 2016, Automated microchromatography enables multiplexing of immunoaffinity enrichment of peptides to greater than 150 for targeted MS-Based Assays, Anal Chem, 88, 7548, 10.1021/acs.analchem.6b00946 · DOI
  5. Kuhn, 2012, Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma, Mol Cell Proteomics, 11, M111.013854, 10.1074/mcp.M111.013854 · DOI · Paper page
  6. Whiteaker, 2011, Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry, Mol Cell Proteomics, 10, M110.005645, 10.1074/mcp.M110.005645 · DOI · Paper page
  7. Machleidt, 2015, NanoBRET–a novel BRET platform for the analysis of protein-protein interactions, ACS Chem Biol, 10, 1797, 10.1021/acschembio.5b00143 · DOI · Paper page
  8. Zhu, 2011, Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide, Blood, 118, 4771, 10.1182/blood-2011-05-356063 · DOI · Paper page
  9. Greenberg, 2013, Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels, Eur J Haematol, 91, 504, 10.1111/ejh.12192 · DOI
  10. Schuster, 2014, The clinical significance of cereblon expression in multiple myeloma, Leuk Res, 38, 23, 10.1016/j.leukres.2013.08.015 · DOI · Paper page
  11. Meyers, 2017, Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells, Nat Genet, 49, 1779, 10.1038/ng.3984 · DOI · Paper page
  12. Petzold, 2016, Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase, Nature, 532, 127, 10.1038/nature16979 · DOI · Paper page
  13. Dimopoulos, 2019, Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma, Leuk Lymphoma, 60, 180, 10.1080/10428194.2018.1466290 · DOI
  14. Krönke, 2017, IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM), Leukemia, 31, 1363, 10.1038/leu.2016.384 · DOI · Paper page
  15. Zhu, 2014, Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma, Blood, 124, 536, 10.1182/blood-2014-02-557819 · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Sperling, A. S., Burgess, M., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Słabicki, M., Sellar, R. S., Fink, E. C., Miller, P. G., Liddicoat, B. J., Sievers, Q. L., Sharma, R., Adams, D. N., Olesinski, E. A., Fulciniti, M., Udeshi, N. D., Kuhn, E., Letai, A., Munshi, N. C., Carr, S. A., & Ebert, B. L.
Venue
Blood
Published
2019-07-11
Volume
134
Issue
2
Pages
160-170
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2943602952
Cited by
64
References
27
FWCI
2.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. https://app.cochat.ai/papers/10.1182/blood.2019000789
The paper
Sperling, A. S., Burgess, M., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Słabicki, M., Sellar, R. S., Fink, E. C., Miller, P. G., Liddicoat, B. J., Sievers, Q. L., Sharma, R., Adams, D. N., Olesinski, E. A., Fulciniti, M., Udeshi, N. D., Kuhn, E., Letai, A., . . . Ebert, B. L. (2019). Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. https://doi.org/10.1182/blood.2019000789

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.